Solid Biosciences to Participate at Chardan’s 8th Annual Genetic Medicines Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its participation in Chardan's 8th Annual Genetic Medicines Conference. The event will feature a fireside chat with Bo Cumbo, President and CEO, and Dr. Gabriel Brooks, Chief Medical Officer, scheduled for Monday, September 30, 2024, at 11:00 am ET.
Interested parties can access a live webcast of the fireside chat through the Events page of the Investors section on Solid Biosciences' website. A replay of the webcast will be available for 30 days after the event. Institutional investors wishing to meet with the management team during the conference are advised to contact their Chardan representatives.
Solid Biosciences Inc. (Nasdaq: SLDB), un'azienda di scienze della vita focalizzata sullo sviluppo di medicine genetiche di precisione per malattie neuromuscolari e cardiache, ha annunciato la sua partecipazione all'8ª Conferenza Annuale sulle Medicine Genetiche di Chardan. L'evento includerà una chiacchierata informale con Bo Cumbo, Presidente e CEO, e Dr. Gabriel Brooks, Direttore Medico, programmata per lunedì 30 settembre 2024, alle 11:00 ET.
Le parti interessate possono accedere a una trasmissione in diretta della chiacchierata informale attraverso la pagina Eventi della sezione Investitori sul sito web di Solid Biosciences. Una registrazione della trasmissione sarà disponibile per 30 giorni dopo l'evento. Gli investitori istituzionali che desiderano incontrare il team di gestione durante la conferenza sono invitati a contattare i propri rappresentanti Chardan.
Solid Biosciences Inc. (Nasdaq: SLDB), una empresa de ciencias de la vida centrada en el desarrollo de medicamentos genéticos de precisión para enfermedades neuromusculares y cardíacas, ha anunciado su participación en la 8ª Conferencia Anual de Medicamentos Genéticos de Chardan. El evento contará con una charla informal con Bo Cumbo, Presidente y CEO, y Dr. Gabriel Brooks, Médico Jefe, programada para lunes 30 de septiembre de 2024, a las 11:00 a.m. ET.
Las partes interesadas pueden acceder a una transmisión web en vivo de la charla informal a través de la página de Eventos en la sección de Inversores del sitio web de Solid Biosciences. Una repetición de la transmisión estará disponible durante 30 días después del evento. Se aconseja a los inversores institucionales que deseen reunirse con el equipo de dirección durante la conferencia que contacten a sus representantes de Chardan.
Solid Biosciences Inc. (Nasdaq: SLDB)는 신경근 및 심장 질환에 대한 정밀 유전자 의약품 개발에 초점을 맞춘 생명 과학 회사로, Chardan의 제8회 연례 유전자 의약품 컨퍼런스에 참여한다고 발표했습니다. 이 행사에서는 Bo Cumbo 사장兼 CEO와 Dr. Gabriel Brooks 수석 의학 책임자가 참여하는 대담이 예정되어 있으며, 이는 2024년 9월 30일 월요일 오전 11:00 ET로 예정되어 있습니다.
관심 있는 분들은 Solid Biosciences 웹사이트의 투자자 섹션의 이벤트 페이지를 통해 이 대담의 생중계를 시청할 수 있습니다. 행사가 끝난 후 30일 동안 재방송을 이용할 수 있습니다. 회의 중 경영진과의 만남을 원하는 기관 투자자는 Chardan의 담당자에게 연락하시기 바랍니다.
Solid Biosciences Inc. (Nasdaq: SLDB), une société de sciences de la vie axée sur le développement de médicaments génétiques de précision pour les maladies neuromusculaires et cardiaques, a annoncé sa participation à la 8e Conférence Annuelle sur les Médicaments Génétiques de Chardan. L'événement comprendra une discussion informelle avec Bo Cumbo, Président et CEO, et Dr. Gabriel Brooks, Médecin en Chef, prévue pour lundi 30 septembre 2024, à 11h00 ET.
Les parties intéressées peuvent accéder à un webcast en direct de la discussion informelle via la page Événements de la section Investisseurs sur le site Web de Solid Biosciences. Une rediffusion du webcast sera disponible pendant 30 jours après l'événement. Les investisseurs institutionnels souhaitant rencontrer l'équipe de direction lors de la conférence sont invités à contacter leurs représentants de Chardan.
Solid Biosciences Inc. (Nasdaq: SLDB), ein Unternehmen der Lebenswissenschaften, das sich auf die Entwicklung präziser genetischer Medikamente für neuromuskuläre und kardiale Erkrankungen konzentriert, hat seine Teilnahme an der 8. Jährlichen Konferenz für Genetische Medikamente von Chardan bekannt gegeben. Bei der Veranstaltung wird ein informelles Gespräch mit Bo Cumbo, Präsident und CEO, und Dr. Gabriel Brooks, Ärztlicher Direktor, stattfinden, das auf Montag, den 30. September 2024, um 11:00 Uhr ET angesetzt ist.
Interessierte Personen können über die Veranstaltungsseite im Investorenbereich der Website von Solid Biosciences auf einen Live-Stream des informellen Gesprächs zugreifen. Eine Aufzeichnung des Streams ist 30 Tage nach der Veranstaltung verfügbar. Institutionelle Investoren, die während der Konferenz mit dem Management-Team zusammentreffen möchten, sollten ihre Chardan-Vertreter kontaktieren.
- None.
- None.
CHARLESTOWN, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat at Chardan’s 8th Annual Genetic Medicines Conference on Monday, September 30, 2024, at 11:00 am ET.
A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.
Institutional investors interested in meeting with management during the conferences may reach out to their Chardan representatives.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
When is Solid Biosciences (SLDB) participating in Chardan's Genetic Medicines Conference?
Who will represent Solid Biosciences (SLDB) at the Chardan conference?
How can investors access the Solid Biosciences (SLDB) fireside chat at the Chardan conference?
What type of medicines does Solid Biosciences (SLDB) develop?
How long will the webcast replay of Solid Biosciences' (SLDB) fireside chat be available?
